For three years, U.S. importers of Korean cosmetics treated MoCRA compliance as a deadline to watch rather than a rule to fear. That window is closing. In 2026, the Modernization of Cosmetics Regulation Act of 2022 stops being a registration exercise and starts being an enforcement reality — biennial renewals are coming due, a public adverse-event dashboard is live, and unlisted products can be refused at the border. If you bring Korean beauty into the United States, here is what actually matters this year.
What MoCRA requires, in plain terms
MoCRA was the biggest expansion of FDA cosmetics authority since 1938. It added several obligations to the Food, Drug, and Cosmetic Act that now apply to most cosmetics sold in the U.S.:
- Facility registration. Every facility that manufactures or processes cosmetics for the U.S. market must register with the FDA. The operative compliance date was July 1, 2024.
- Product listing. Each marketed product must be listed with the FDA, with annual updates. Registration and listing are filed through the FDA’s Cosmetics Direct portal (forms FDA 5066 and 5067).
- A Responsible Person. The manufacturer, packer, or distributor named on the label carries the listing, adverse-event, and safety obligations.
- Adverse event reporting. Serious adverse events must be reported to the FDA within 15 business days, with records kept for six years.
- Safety substantiation. The Responsible Person must hold records adequately substantiating each product’s safety.
2026 is the year of the renewal
The detail catching importers off guard: facility registrations must be renewed every two years, and the first renewals come due in 2026, tied to each facility’s original registration date. A facility first registered in February 2024 must renew by February 2026. The FDA updated Cosmetics Direct in early 2026 with registration-status and renewal-date fields — a clear signal that the agency is tracking who has lapsed.
Enforcement posture has hardened in step. The FDA launched a public, searchable serious-adverse-event dashboard in late 2025, issued warning letters citing product-listing failures, and published draft guidance on its authority to demand records where it believes a product is adulterated. For imports, the consequence is concrete: products from an unregistered facility, or that are not properly listed, are subject to detention and refusal at the border.
The “Responsible Person” trap for Korean brands
This is the single most misunderstood concept for importers of Korean cosmetics. The Responsible Person must be the entity named on the product label — and a Korean factory sitting overseas generally cannot serve that role for U.S. distribution. In practice, the U.S. importer, distributor, or brand owner becomes the Responsible Person and inherits the listing, adverse-event reporting, and safety-substantiation liability.
That means the compliance burden does not stay in Seoul. It lands on whoever is bringing the product into the country. A separately registered foreign facility must also designate a U.S. agent. Getting this structure wrong is how importers end up personally exposed to obligations they assumed the manufacturer was carrying.
What’s delayed — and why that’s a trap
Two MoCRA rules are running behind schedule, and complacency about them is its own risk. The fragrance-allergen labeling rule — which will require disclosing individual allergens rather than the generic “fragrance” — is now expected as a proposed rule around mid-2026, with a final rule and compliance date likely not before 2027. The cosmetics GMP rule, expected to track ISO 22716, has also slipped with no firm date.
The trap is reading “delayed” as “optional.” Facility registration, product listing, adverse-event reporting, and safety substantiation are all enforceable today. The delayed rules add future work; they do not relieve the current obligations.
A note on the small-business exemption
Businesses averaging under $1 million in annual U.S. cosmetic sales are exempt from facility registration, product listing, and GMP — but the exemption does not extend to products that contact the eye’s mucous membrane, are injected, are for internal use, or alter appearance for more than 24 hours. And it never waives adverse-event reporting or safety substantiation. Many importers misjudge where they fall.
The operator’s view
MoCRA’s grace period is effectively over, and the importer — not the Korean manufacturer — usually holds the liability. At Luxmetics, we handle U.S. MoCRA registration, serve as or stand behind the Importer of Record, and manage the Responsible Person structure end to end, so Korean products clear the border and stay compliant after they land. If you are importing Korean cosmetics in 2026, this is the part you do not want to improvise.
Leave a Reply